(I-BusinessNews.Com, November 08, 2019 ) Colorectal Cancer
• Colorectal cancer (CRC) is referred to as malignancies that will originate in the rectum or colon also known as bowel cancer.
• The most common feature of colorectal cancer is the formation of adenocarcinomas. The tumor is going to start as a polyp in the inner wall of the colon or rectum, and these polyps may be benign or malignant.
• The risk factors that are involved in causing colorectal cancer include lifestyle changes, genetic disorders, old age, family history, and inflammatory bowel disease.
• Colorectal cancer is symptomized by blood in stool, constipation, a decrease in appetite, weight loss, bloating, nausea, and pelvic pain. Colorectal cancer is categorized into four broad stages. Colorectal cancer is treated by using surgical, radiation, chemotherapeutic, biologic, and immunotherapies.
• Most of the cases of CRC are presented as adenocarcinomas tumors, but other types of CRC involve gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, primary colorectal lymphoma, gastrointestinal stromal tumors, leiomyosarcoma, squamous cell carcinoma, and melanoma.
• The investigational pipeline candidates that are currently under the treatment therapies include promising immunotherapies and chemotherapy drug candidates as well as new combination therapies and targeted therapy drug candidates.
• These drug candidates fall across all stages of clinical development, among which the majority are being in preclinical and phase I.
• Further investigation shows that more CRC drug candidates currently are found in discovery, an investigational new drug (IND)/clinical trial application (CTA) filed phases compared to that in phase III. It shows that there are many more upcoming opportunities, which will increase the development of colorectal cancer products through all the clinical stages.
• Further, this moderate growth will be hindered by the uptake of lower-priced biosimilar versions of cetuximab and bevacizumab due to the expiration of the patent of Avastin and Erbitux.
• It is also expected that the introduction of generic versions of capecitabine will also affect market growth. However, this can be balanced by the introducing premium-priced emerging therapies.
• One of the biggest drivers of growth in the CRC market is expected to be Stivarga drug treatment, firstly due to the scheduled line extension as a maintenance treatment drug for patients with resected liver metastases in the first-line metastatic setting.
• The launch of Lonsurf (TAS-102) found in the third and fourth-line settings is going to further increase the rates of pharmacological treatment in these lines that will provide the patients a more tolerable alternative to Stivarga treatment.
• The moderate expected uptake of other late-stage pipeline products like panitumumab and Xilonix, following the expected approval, is going to drive additional growth within the market.
• The primary drivers of growth include the expected increased number of diagnosed CRC incidence cases and the launch and uptake of the premium-priced therapies for treatment.
• Traditionally, two therapeutic classes have dominated the CRC market including Angiogenesis and EGFR inhibitors. The prediction that the branded drugs used to facilitate the gradual increase in the number of patients. With branded therapy across different lines of metastatic treatment, an increase in the patient pool of these segments and also the overall CRC market size shall be noticed.
• Loss of patent exclusivity of many developers is going to challenge for introducing new candidates that will increase the growth of the market. The dominated natures of biologics among other therapeutics are the trending currently in the market.
Market Outlook
• Colorectal cancer (CRC) is referred to as malignancies that will originate in the rectum or colon also known as bowel cancer.
• The most common feature of colorectal cancer is the formation of adenocarcinomas. The tumor is going to start as a polyp in the inner wall of the colon or rectum, and these polyps may be benign or malignant.
• The risk factors that are involved in causing colorectal cancer include lifestyle changes, genetic disorders, old age, family history, and inflammatory bowel disease.
• Colorectal cancer is symptomized by blood in stool, constipation, a decrease in appetite, weight loss, bloating, nausea, and pelvic pain. Colorectal cancer is categorized into four broad stages. Colorectal cancer is treated by using surgical, radiation, chemotherapeutic, biologic, and immunotherapies.
• Most of the cases of CRC are presented as adenocarcinomas tumors, but other types of CRC involve gastrointestinal carcinoid tumors, gastrointestinal stromal tumors, primary colorectal lymphoma, gastrointestinal stromal tumors, leiomyosarcoma, squamous cell carcinoma, and melanoma.
• The investigational pipeline candidates that are currently under the treatment therapies include promising immunotherapies and chemotherapy drug candidates as well as new combination therapies and targeted therapy drug candidates.
What’s trending in this market?
• These drug candidates fall across all stages of clinical development, among which the majority are being in preclinical and phase I. It shows that 68% of the colorectal cancer drug candidates (CRC) are in preclinical and phase I, among which 45% are in preclinical, and 23% are in phase I stage of development.
• Further investigation shows that more CRC drug candidates currently are found in discovery, an investigational new drug (IND)/clinical trial application (CTA) filed phases compared to that in phase III.
• It shows that there are many more upcoming opportunities, which will increase the development of colorectal cancer products through all the clinical stages.
• Further, this moderate growth will be hindered by the uptake of lower-priced biosimilar versions of cetuximab and bevacizumab due to the expiration of the patent of Avastin and Erbitux. It is also expected that the introduction of generic versions of capecitabine will also affect market growth.
• However, this can be balanced by the introducing premium-priced emerging therapies. One of the biggest drivers of growth in the CRC market is expected to be Stivarga drug treatment, firstly due to the scheduled line extension as a maintenance treatment drug for patients with resected liver metastases in the first-line metastatic setting.
• The launch of Lonsurf (TAS-102) found in the third and fourth-line settings is going to further increase the rates of pharmacological treatment in these lines that will provide the patients a more tolerable alternative to Stivarga treatment.
• The moderate expected uptake of other late-stage pipeline products like panitumumab and Xilonix, following the expected approval, is going to drive additional growth within the market.
Drivers & Restraints
• The primary drivers of growth include the expected increased number of diagnosed CRC incidence cases and the launch and uptake of the premium-priced therapies for treatment.
• Traditionally, two therapeutic classes have dominated the CRC market including Angiogenesis and EGFR inhibitors. The prediction that the branded drugs used to facilitate the gradual increase in the number of patients.
• With branded therapy across different lines of metastatic treatment, an increase in the patient pool of these segments and also the overall CRC market size shall be noticed.
• Loss of patent exclusivity of many developers is going to challenge for introducing new candidates that will increase the growth of the market. The dominated natures of biologics among other therapeutics are the trending currently in the market.
Enquire Before Purchase: https://www.datamintelligence.com/enquiry/colorectal-cancer
Download free sample: https://www.datamintelligence.com/download-sample/colorectal-cancer
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
